Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine effects on coronary plaque burden and composition in patients undergoing clinically indicated coronary angiography
NL-OMON38424Phase 3Withdrawn
- Sponsor
- Servier
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis comparing Ivabradine with Placebo (2 arms). Primary endpoint: Change in coronary percent atheroma volume. Planned start Feb 2013; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON38424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38424.